Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He discusses the updated analysis of the KEYNOTE-199 study (KEYNOTE-199), which investigated pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.